Bayer and Johnson & Johnson received FDA approval to promote Xarelto, an oral factor Xa inhibitor, for stroke prevention among patients with nonvalvular atrial fibrillation. The agency assigned a black-box warning that advises against discontinuation of therapy without medical advice. Xarelto, or rivaroxaban, was originally indicated as anti-clotting treatment after knee- or hip-replacement surgery.

Related Summaries